• #NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
  • New Mutations Account for Genetically Unsolved Cases of EBS, Researchers Say
  • Abeona to Advance Gene Therapy Research at Commercial Manufacturing Facility in Ohio
  • Austrian Researchers Develop New Formulation of Diacerein to Treat EBS
  • Fibrocell Reports Positive Results of Phase 1/2 Trial of FCX-007 Gene Therapy for RDEB
  • Efforts Ramping Up to Treat EB: Interview with DEBRA
  • Life with EB: Tough, Time-Consuming, and Fraught with Risk
  • FDA Grants Orphan Drug Status to ProQR’s QR-313 as Treatment for Dystrophic EB
  • InMed’s Cannabinoid-based Manufacturing System Covered in New Patent Application
  • Amicus’ SD-101 Cream Misses Goals in Epidermolysis Bullosa Phase 3 Trial
  • CRISPR/Cas9 RNP System Shown to Be Effective for Gene Editing in Epidermolysis Bullosa Mice
  • Low Vitamin D Levels, More Severe Disease Linked to Poor Bone Health in Kids with EB, Study Finds